Skip to content
10-Q

Quarterly Report

XERIS BIOPHARMA HOLDINGS, INC. XERS

0001867096-25-000089

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 160.16M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $217.81M
Long Term Debt Q1 2025 · Dec 31, 2024 $217.01M
Short Term Debt Q1 2025 · Mar 31, 2025 $11.96M
Short Term Debt Q1 2025 · Dec 31, 2024 $15.1M
Current Liabilities Q1 2025 · Mar 31, 2025 $95.07M
Current Liabilities Q1 2025 · Dec 31, 2024 $100.44M
Total Liabilities Q1 2025 · Mar 31, 2025 $350.58M
Total Liabilities Q1 2025 · Dec 31, 2024 $352.68M
Current Assets Q1 2025 · Mar 31, 2025 $163.49M
Current Assets Q1 2025 · Dec 31, 2024 $167.66M
Total Assets Q1 2025 · Mar 31, 2025 $315.45M
Total Assets Q1 2025 · Dec 31, 2024 $323.06M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $71.62M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $62.69M
Shares Diluted Q1 2025 · Mar 31, 2024 140.51M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$20.3M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$9.18M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$6.78M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.14
Eps Basic Q1 2025 · Mar 31, 2024 −$0.14
Sga Expense Q1 2025 · Mar 31, 2024 $38.38M
Rd Expense Q1 2025 · Mar 31, 2024 $7.82M
Net Income Q1 2025 · Mar 31, 2024 −$18.98M
Operating Income Q1 2025 · Mar 31, 2024 −$14.25M
Revenue Q1 2025 · Mar 31, 2024 $40.64M